Versican proteolysis predicts immune effector infiltration and post-transplant survival in myeloma. Leuk Lymphoma 2019 Oct;60(10):2558-2562
Date
03/09/2019Pubmed ID
30845856Pubmed Central ID
PMC7176050DOI
10.1080/10428194.2019.1585836Scopus ID
2-s2.0-85062788299 (requires institutional sign-in at Scopus site) 12 CitationsAuthor List
Dhakal B, Pagenkopf A, Mushtaq MU, Cunningham AM, Flietner E, Morrow Z, Papadas A, Hope C, Leith C, Hematti P, Hari P, Callander NS, Asimakopoulos FAuthors
Ashley Cunningham MD Associate Professor in the Pathology department at Medical College of WisconsinBinod Dhakal MD Associate Professor in the Medicine department at Medical College of Wisconsin
Parameswaran Hari MD Adjunct Professor in the Medicine department at Medical College of Wisconsin
Peiman Hematti MD Professor in the Medicine department at Medical College of Wisconsin
MESH terms used to index this publication - Major topics in bold
BiomarkersHematopoietic Stem Cell Transplantation
Humans
Immunohistochemistry
Lymphocytes, Tumor-Infiltrating
Multiple Myeloma
Prognosis
Proteolysis
Treatment Outcome
Tumor Microenvironment
Versicans